Results 191 to 200 of about 164,783 (254)

Endometrial Epithelial Lactate Deficiency Drives CD8+ T‐Cells Dysregulation in Unexplained Recurrent Implantation Failure

Advanced Science, EarlyView.
Unexplained recurrent implantation failure (RIF) represents a significant clinical challenge. Our results demonstrate that reduced lactate production in the RIF endometrium impairs the suppression of cytotoxic CD8+ T‑cells, allowing their proliferation and thereby disrupting the local immune balance essential for successful embryo implantation.
Yuanlin He, Kang Ke, Qingxia Meng, Yichun Guan, Jichun Tan, Hong Lv, Boxian Huang, Chan Tian, Qinyan Zou, Mingxing An, Yao Gao, Jingjing Chen, Xiaoyu Wei, Xi Wang, Hongxia Ma, Yuan Lin, Feiyang Diao, Yayun Gu, Zhibin Hu   +18 more
wiley   +1 more source

Thrombotic Microangiopathy after a 15-year Treatment with Interferon Beta-1b in a Patient with Multiple Sclerosis: A Case Report and Review of Literature. [PDF]

Intern Med
Akita S, Fujibayashi K, Ueno EI, Wakasa M, Kawai Y, Kajinami K.   +5 more
europepmc   +1 more source

Nanozymes for Liver Disease Therapy: Advances in Catalytic Activity, Targeting Strategies, and Clinical Translation

Advanced Science, EarlyView.
Nanozymes, as enzyme‐mimicking nanomaterials, exhibit unique catalytic properties for the treatment of liver diseases. By regulating redox homeostasis, modulating immune responses, and enabling targeted delivery, nanozymes overcome the limitations of natural enzymes.
Xiandi Meng, Ge Zhu, Siyu Sun, Wenbo Yao, Yuning Zhang, Yong‐Guang Yang, Tianmeng Sun   +6 more
wiley   +1 more source

Post‐Translational Regulation of CD8+ T Cell Fate and Dysfunction in Tumor Immunity

Advanced Science, EarlyView.
This review delineates how post‐translational modifications (PTMs) function as a central regulatory interface governing CD8+ T cell activation, differentiation, persistence, and exhaustion in antitumor immunity. By integrating antigenic, metabolic, and microenvironmental cues, diverse PTM programs coordinate transcriptional and chromatin states that ...
Zihao Zhou, Xu Chen, Nina Li, Meiyan Zou, Yunfan Lin, Pei Lin, Weiyao Feng, Xinyuan Zhao, Li Cui   +8 more
wiley   +1 more source

Programmable RNA N6,2´‐O‐Dimethyladenosine Editing

Advanced Science, EarlyView.
ABSTRACT N6,2’‐O‐dimethyladenosine (m6Am) is a prevalent RNA modification located at the first transcribed nucleotide adjacent to the 5′ cap of mRNAs, where it has been implicated in gene regulation. However, the lack of methods for precise, transcript‐specific manipulation of m6Am has limited its functional dissection.
Yang Li, Xiangmin Tan, Yaran Liu, Yongquan He, Bo Yuan, Ping Wang, Guangzhi Ma, Mengzhe Guo, Jian Zhou, Qiang Sun   +9 more
wiley   +1 more source

Cloning and Functional Characterization of Novel Human Neutralizing Anti-IFN-α and Anti-IFN-β Antibodies. [PDF]

J Immunol
Papasavvas E, Lu L, Fair M, Oliva I, Cassel J, Majumdar S, Mounzer K, Kostman JR, Tebas P, Bar-Or A, Muthumani K, Montaner LJ.   +11 more
europepmc   +1 more source

Some of the next articles are maybe not open access.

Related searches:

Interaction of PEGylated interferon-beta with antibodies to recombinant interferon-beta

International Immunopharmacology, 2018
Because PEGylated molecules exhibit different physicochemical properties from those of the parent molecules, PEGylated interferonβ-1a (pegIFNβ-1a) may be able to be used with retained bioactivity in Multiple Sclerosis (MS) patients who have previously developed neutralizing antibodies (NABs) to recombinant interferonβ (rIFNβ).
Francesca, Gilli, Adrianna L, De La Torre, Darlene B, Royce, Andrew R, Pachner   +3 more
openaire   +2 more sources

Interferon Beta-1a

Hospital Pharmacy, 2002
Each month, subscribers to The Formulary® Monograph Service receive five to six well-documented monographs on drugs that are newly released or are in late Phase III trials. The monographs are targeted to your Pharmacy and Therapeutics Committee. Subscribers also receive monthly one-page summary monographs on the agents that are useful for agendas and ...
Dennis J. Cada, Terri Levien, Danial E. Baker   +2 more
openaire   +1 more source

Interferon-beta

Reactions Weekly, 2023
  +4 more sources